PV

Philippe V. Klitzing

Partner at Peak

Berlin, Berlin

Overview 

Philippe v. Klitzing is currently a Partner at Peak, specializing in Mergers & Acquisitions and Private Equity. With a background in Investment Banking and a Master's degree from The London School of Economics, he has successfully managed various investments and served as a board observer for multiple companies, including Valispace which had a successful exit to Altium.

Work Experience 

P

Peak

  • Partner

    2023 - Current

  • Investment Manager

    2023 - 2023

O

Outcome

  • Investor

    2024

PE

PLATFORM ENGINEERING LABS Inc.

  • Investor

    2024

F

Frontnow

  • Investor

    2024

E

Enersee

  • Investor

    2023

JC

JOIN CAPITAL

  • Associate

    2021 - 2022

  • Analyst

    2019 - 2021

CS

CEPTON Strategies

  • Strategy Consultant

    2018 - 2019

    CEPTON is a leading boutique strategy consultancy serving mid to large corporations in areas of strategy and organisation as well as financial investors for due diligences. Examples of projects include: - Strategic due diligence projects for private equity funds (i.e. aesthetics, analytical testing) - Streamlining of product portfolio for a pharma and dermo-cosmetic company - Market analysis of patient support & prevention programs in Germany for a leading HCP - Structuring and implementation of a strategic alliance project between two FinTechs - Optimisation of the international investment strategy for a large French pharma company

commeunearmoire

  • Co-founder & COO

    2015 - 2017

    Innovative, next generation storage company to take the pain out of using a traditional storage unit by offering a by-the-box service. - Winner of the Prix du Public of the Startup Academy 2015 - Runner-Up of the Moovjee 2016 Prize - Winner of the EnModeUp! Accelerator Program 2016 Acquisitions: Wesquare (2015), La Boite Qui Cartonne (2016), remaining activity from Boxon (2016) Commeunearmoire's activity was sold to Stocketmoi in November 2017.

B

Bpifrance

  • Junior Analyst Venture Capital

    2014 - 2014

    Large Venture is a €1bn vehicle investing in high-growth innovative companies with significant capital requirements in the biotech & healthcare, digital, and green tech spaces. Large Venture invests in VC-backed companies (or validated by significant revenue traction) thus continuing and leveraging the financing started by early-stage investors. Played an active role in four minority investments: - Poxel (€10m): drug development for Type 2 diabetes (spin-off from Merck) - TxCell (€8m): autologous cellular therapies for patients suffering from Crohn's disease - Pixium Vision (€15m): Intelligent retinal implant device that aims to recover a near normal vision for people who lost their sight due to degenerative disorders of the eye - DBV Technologies (€15m): innovative solutions in the field of food and pediatric allergies

R

Rothschild

  • M&A Intern, Global Financial Advisory

    2013 - 2014

Education 

Articles About Philippe V.

Relevant Websites